Grygoriy Rekhtman Selected Research

B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)

1/2020	A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial.
1/2017	Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.
1/2016	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Grygoriy Rekhtman Research Topics

Disease

3	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 01/2016

Drug/Important Bio-Agent (IBA)

3	fludarabineIBA 01/2020 - 01/2016
3	ofatumumab FDA Link 01/2020 - 01/2016
2	Complement C2 (Complement Component 2)IBA 01/2020 - 01/2017
2	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020 - 01/2017

Therapy/Procedure

1	Therapeutics 01/2016